Good news for Ironwood, which forecast annual sales of up to $300m, despite black box kidney failure warning.
Earlier decision to reject drug reversed.
Otezla gains NICE approval for psoriatic arthritis
Otezla cheap and convenient, but less effective than rivals, says NICE.
NICE says Otezla’s bargain price offsets lower efficacy
But attendees warned to expect “oceanic” weather.
Janssen’s RA candidate among hot topics at EULAR